pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Rare Disease · news · pharmadog
← back to Rare Disease
News mentioning Rare Disease
225
stories
24d
STAT+: Bracing for another Fauci hearing
stat
24d
STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
stat
24d
As pharma descends on China for deals, BIOSECURE Act raises intellectual property risk
biospace
25d
Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail
biospace
25d
FDA scientists question Capricor data; Legend CEO steps down
biopharma dive
25d
RA Capital launches rare disease company Oak Hill Bio onto Nasdaq via SPAC
fiercebiotech
25d
STAT+: Sarepta names Michael Severino, former Tessera CEO, as new chief executive
stat
25d
STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more
stat
25d
STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
stat
25d
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
biospace
25d
A trend that isn’t fading, ultra-processed baby foods
stat
25d
STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease
stat
25d
Updated: AstraZeneca foresees blockbuster sales for Claudin 18.2 ADC, but Ultomiris flops in rare disease
endpoints
25d
STAT+: As some medical schools embrace RFK Jr.’s nutrition push, they deftly sidestep MAHA priorities
stat
25d
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
28d
FDA advisory panel narrowly rejects compounding of one peptide, backs two others
stat
28d
Amgen shares new Tavneos analysis in effort to resolve FDA dispute
endpoints
28d
Amgen sheds around 40 staffers amid continuing struggles
fiercebiotech
28d
Amgen deploys patients to defend troubled Tavneos in FDA hearing request
biospace
28d
STAT+: Fatal gene-editing trial in China raises ethics and oversight questions
stat
28d
CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa
endpoints
28d
STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides
stat
29d
STAT+: What’s in the last-minute flurry of health care bills?
stat
29d
FDA panel confronting peptide controversy
stat
29d
A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
stat
29d
STAT+: FDA staff and peptide enthusiasts set to clash at advisory panel
stat
29d
Make or break: Commercial hires critical for success
biospace
29d
Webinar: From Clinical to Commercial: Talent Strategies for Biopharma Growth
biospace
Jul 22, 26
Opinion: What Argentina’s World Cup loss should teach American hospitals
stat
Jul 22, 26
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
biopharma dive
← prev
page 4 of 8
next →
